ReviewThe World Allergy Organization journal2019
Developing pharmacogenetic screening methods for an emergent country: Vietnam.
Review in The World Allergy Organization journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis.Clinical and translational science · 2022Pooled it
- Machine learning-based model for prediction of carbamazepine- and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.The World Allergy Organization journal · 2026Article
- Research progress on potential high-risk drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis with insights from adverse drug reaction database mining.Frontiers in pharmacology · 2026Review
- Genotype Frequency ofDiagnostics (Basel, Switzerland) · 2025Article
- The application of genetic testing technology in kidney transplantation: precision matching, non-invasive monitoring and personalized management.Frontiers in immunology · 2025Review
- Article
- Cost-effectiveness ofPharmacogenomics · 2023Article
- The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam.Frontiers in pharmacology · 2023Article
- Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity.The journal of allergy and clinical immunology. In practice · 2022Article
- A Comprehensive Review ofPharmaceuticals (Basel, Switzerland) · 2021Review
- Genetic Determinants inJournal of personalized medicine · 2021Review
- Enhancing Permeation of Drug Molecules Across the Skin via Delivery in Nanocarriers: Novel Strategies for Effective Transdermal Applications.Frontiers in bioengineering and biotechnology · 2021Review
- A Novel Allele-Specific PCR Protocol for the Detection of theThe application of clinical genetics · 2021Article
- Review on Databases and Bioinformatic Approaches on Pharmacogenomics of Adverse Drug Reactions.Pharmacogenomics and personalized medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe finding of strong associations between certain human leukocyte antigen (HLA) genotypes and the development of severe cutaneous adverse drug reactions (SCARs), [for example, HLA-B*57:01 and abacavir (ABC), HLA-B*15:02 and carbamazepine (CBZ) and HLA-B*58:01 and allopurinol], has led to HLA screening being used to prevent SCARs. Screening has been shown to be of great benefit in a number of studies. Clinical translation from bench to bedside, however, depends upon the development of simple, rapid and cost-effective assays to detect these risk alleles. In highly populated developing countries such as Vietnam, where there is a high prevalence of HLA-B*15:02 and HLA-B*58:01 correlating with a high incidence of CBZ- and allopurinol-induced SCARs, the crucial factor in the implementation of comprehensive screening programs to detect these major risk HLA alleles is the availability of suitable assays. BODY: We have summarized the role and economic benefits of HLA screening, reviewed published HLA screening methods used currently in pharmacogenetic screening and examined the advantages and disadvantages of assays developed specifically for use in screening for risk alleles in the prevention of HLA-associated SCARs in Vietnam.
conclusionThe optimal approach we propose may serve as a template for the development of screening programs in other emergent countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.